Spinet.ru - ,
 
(0/27314) (0/451) (0/457) (0/901)

 
24 ,
-
  •    
  •    
  •    
  •    
  •    
  •    
  •    
  •    
 
 
 
 
,
 
 
 
-
 
 
 
 
 
 
,
 
 

 
 
 
 
 

    ← 2026 →
    123456
    78910111213
    14151617181920
    21222324252627
    282930
 
 
, , -
  •           
  •           
  •           
 
 

 
 

     
 

 

 

 
 

:
, ,
 
 


2

 

 

  1. Okada M, K. T. (2013). Periodontal Treatment Decreases Levels of Antibodies to Porphyromonas Gingivalis and Citrulline in Patients with Rheumatoid Arthritis and Periodontitis. J Periodontol, 84(12), e74-84.
  2. Oliveria SA, F. D. (1999). Body weight, body mass index, and incident symptomatic osteoarthritis of the hand, hip, and knee. Epidemiology, 10(2), 161-6.
  3. Olivero U, S. G.–P. (1991). Effects of treatment with matrix on elderly people with chronic articular degeneration. Drugs Exp. Clin. Res(17), 45-21.
  4. Olsson AR, S. T. (2000). Occupational determinants for rheumatoid arthritis. Scand J Work Environ Health, 26(3), 243-9.
  5. Oregon Evidence-based Practice Center. (October 2011). Comparative Effectiveness and Safety of Analgesics for Osteoarthritis: An Update of the 2006 Comparative Effectiveness Review, Comparative Effectiveness Review No. 38. for the Agency for Healthcare Research and Quality.
  6. Osiri M, W. V. (2000). Transcutaneous electrical nerve stimulation for knee osteoarthritis. Cochrane Database of Systematic Reviews(4), CD002823.
  7. Ottawa Panel Evidence-Based Clinical Practice. (2005). Guidelines for Therapeutic Exercises and Manual Therapy in the Management of Osteoarthritis. Phys Ther, 85, 907-971.
  8. Ouchi N, P. J. (2011). Adipokines in inflammation and metabolic disease. Nat Rev Immunol, 11(2), 85-97.
  9. Palma Dos Reis R, G. G. (2011). Crystalline glucosamine sulfate in the treatment of osteoarthritis: evidence of long-term cardiovascular safety from clinical trials. Open Rheumatol J(5), 6977.
  10. Pang L, H. C. (2013). Pseudogout-associated inflammatory calcium pyrophosphate dihydrate microcrystals induce formation of neutrophil extracellular traps. J Immunol, 190(12), 6488-500.
  11. Papadopoulos NG, A. Y. (2005). Does cigarette smoking influence disease expression, activity and severity in early rheumatoid arthritis patients? Clin Exp Rheumatol, 23(6), 861-866.
  12. Patel SB, Eastmond CJ. (1983). Preceding tonsillectomy and appendicectomy in rheumatoid and degenerative arthritis. J Rheumatol, 10(2), 313-5.
  13. Pattison DJ, H. R. (2004). The role of diet in susceptibility to rheumatoid arthritis: a systematic review. J Rheumatol, 31(7), 1310-9.
  14. Pattison DJ1, S. A. (2004). Vitamin C and the risk of developing inflammatory polyarthritis: prospective nested case-control study. Ann Rheum Dis, 63(7), 843-7.
  15. Pattison DJ1, S. D. (2004). Dietary risk factors for the development of inflammatory polyarthritis: evidence for a role of high level of red meat consumption. Arthritis Rheum, 50(12), 3804-12.
  16. Pearson CM. (1956). Development of arthritis, periarthritis and periostitis in rats given adjuvants. Proc Soc Exp Biol Med, 91(1), 95-101.
  17. Peat G, M. R. (2001). Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis, 60, 91-7.
  18. Peat G, T. E. (2007). Estimating the probability of radiographic osteoarthritis in the older patient with knee pain. Arthritis Rheum, 57(5), 794-802.
  19. Pedersen M, J. S. (2006). Environmental risk factors differ between rheumatoid arthritis with and without auto-antibodies against cyclic citrullinated peptides. Arthritis Res Ther, 8(4), R133.
  20. Pedersen M, J. S. (2006). Socioeconomic status and risk of rheumatoid arthritis: a Danish case-control study. J Rheumatol, 33(6), 1069-74.
  21. Pedersen M, J. S. (2007). Strong combined gene-environment effects in anti-cyclic citrullinated peptide-positive rheumatoid arthritis: a nationwide case-control study in Denmark. Arthritis Rheum, 56(5), 1146-53.
  22. Pedersen M, S. C. (2005). Diet and risk of rheumatoid arthritis in a prospective cohort. J Rheumatol, 32(7), 1249-52.
  23. Perlman AI, S. A. (2006). Massage therapy for osteoarthritis of the knee: A randomized controlled trial. Archives of Internal Medicine, 166(22), 2533-8.
  24. Peterson K, M. M. (2010). Drug Class Review: Nonsteroidal Antiinflammatory Drugs (NSAIDs): Final Update 4 Report [Internet]. Report [Internet]
  25. Pillemer S, G. P. (2003). Pilot clinical trial of intravenous doxycycline versus placebo for rheumatoid arthritis. J Rheumatol(30), 41-43.
  26. Pladevall-Vila M, D. G.-T.-A. (1996). Controversy of oral contraceptives and risk of rheumatoid arthritis: meta-analysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity. Am J Epidemiol, 144(1), 1-14.
  27. Popa-Nita O, P. S.-L. (2009). Crystal-induced neutrophil activation: XI. Implication and novel roles of classical protein kinase C. J Immunol, 183(3), 2104-14.
  28. Puntis D, M. S. (2013). Urinary tract infections in patients with rheumatoid arthritis. Clin Rheumatol(32), 355-360.
  29. Qvistgaard E, C. R.-P. (2006). Intra-articular treatment of hip osteoarthritis: A randomized trial of hyaluronic acid, corticosteroid, and isotonic saline. Osteoarthritis & Cartilage, 14(2), 163–70.
  30. Raja K, Dewan N. (2011). Efficacy of knee braces and foot orthoses in conservative management of knee osteoarthritis: a systematic review. Am J Phys Med Rehabil, 90(3), 247-62.
  31. Reginster J, D. R. (1999). Glucosamine sulfate significantly reduces progression of knee osteoarthritis over 3 years: a large, randomized, placebo–controlled, prospective trial. Arthr Rheum(42), 400.
  32. Reginster J.I. (2002). The prevalence and burden of arthritis. Register 11 Rheumatology, 41(Suppl 1), 3-6.
  33. Reijman M, P. H.-Z. (2007). Body mass index associated with onset and progression of osteoarthritis of the knee but not of the hip: the Rotterdam Study. Ann Rheum Dis, 66(2), 158-62.
  34. Richette P, P. C. (2011). Benefits of massive weight loss on symptoms, systemic inflammation and cartilage turnover in obese patients with knee osteoarthritis. Ann Rheum Dis, 70(1), 139-44.
  35. Richmond J, et al. (2009). Treatment of Osteoarthritis of the Knee (Nonarthroplasty). J Am Acad Orthop Surg, 17, 591-600.
  36. Richmond J, H. D. (2010). American Academy of Orthopaedic Surgeons Clinical Practice Guideline on The Treatment of Osteoarthritis (OA) of the Knee. J Bone Joint Surg Am, 92, 990-993.
  37. Riemsma RP, K. J. (2003). Patient education for adults with rheumatoid arthritis. Cochrane Database Syst Rev(2), 003688.
  38. Rigby AS, S. A. (1991). Investigating the HLA component in rheumatoid arthritis: an additive (dominant) mode of inheritance is rejected, a recessive mode is preferred. Genet Epidemiol, 8(3), 153-75.
  39. Ringdahl E, Pandit S. (2011). Treatment of Knee Osteoarthritis. American Family Physician, 83(11), 1287-1292.
  40. Rock KL, K. H.-J. (2013). Uric acid as a danger signal in gout and its comorbidities. Nature Reviews Rheumatology, 9, 13-23.
  41. Roddy E. (2011). Revisiting the pathogenesis of podagra: why does gout target the foot? J Foot Ankle Res, http://openi.nlm.nih.gov/detailedresult.php?img=3117776_1757-1146-4-13-1&req=4.
  42. Ropes M.W., B. G. (1956). Proposed diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis(7), 121-4.
  43. Ropes M.W., B. G. (1958). Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis, 9(4), 175-6.
  44. Runhaar J, K. B.-Z. (2011). A systematic review on changed biomechanics of lower extremities in obese individuals: a possible role in development of osteoarthritis. Obes Rev, 12(12), 1071-82.
  45. Russell RI. (1999). Defining patients at risk of non-steroidal anti-inflammatory drug gastropathy. Ital J Gastroenterol Hepatol, 31(Suppl 1), s14-8.
  46. Saag KG, T. G. (2008). American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis . Arthritis Rheum, 59(6), 762–8408.
  47. Scher JU. (2013). Monotherapy in Rheumatoid Arthritis. Bulletin of theHospital for Joint Diseases, 71(3), 204-7.
  48. Schneider, T. M. (2008). Whipple's disease: new aspects of pathogenesis and treatment. Lancet Infect Dis, 8(3), 179-90.
  49. Scott D., Kowalczyk A. (2007). Osteoarthritis of the knee. BMJ Clin Evid, 12(1121), 21.
  50. Scott D., S. . (2005). What are the consequences of early rheumatoid arthritis for the individual? Best Pract.Res.Clin.Rheumatol., 19(1), 117-136.
  51. Scott DL, W. F. (2010). Rheumatoid arthritis. Lancet, 376(9746), 1094-108.
  52. Scott DL, W. F. (2010). Rheumatoid arthritis. Lancet, 376(9746), 1094–108.
  53. Serour M, A. H.-S.-N. (2007). Cultural factors and patients adherence to lifestyle measures. Br J Gen Pract, 57(Suppl 537), 291-295.
  54. Shapiro JA, K. T. (1996). Diet and rheumatoid arthritis in women: a possible protective effect of fish consumption. Epidemiology, 7(3), 256-63.
  55. Shen H, K. D. (2013). Processes of sterile inflammation. J Immunol, 191(6), 2857-63.
  56. Shen H, S. H. (2006). Analgesic action of acetaminophen in symptomatic osteoarthritis of the knee. Rheumatology, 45(6), 765-70.
  57. Sherman G, Z. L. (2009). Intermittent balneotherapy at the Dead Sea area for patients with knee osteoarthritis. Isr Med Assoc J, 11(2), 88-93.
  58. Shichikawa K, I. K. (1999). Changes in the incidence and prevalence of rheumatoid arthritis in Kamitonda, Wakayama, Japan, 1965–1996. Ann Rheum Dis, 58(12), 751-756.
  59. Silman AJ, M. A. (1993). Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol, 32(10), 903-7.
  60. Silman AJ1, M. A. (1993). Twin concordance rates for rheumatoid arthritis: results from a nationwide study. Br J Rheumatol, 32(10), 903-7.
  61. Silverstein F.E. Faich G., G. J. (2000). Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. JAMA, 284, 1247-55.
  62. Silverstein F.E., F. G. (2000). Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA, 284, 1247–1255.
  63. Sivera F, A. M. (2014). Multinational evidencebased recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis, 73(2), 328-35.
  64. Sluis-Cremer GK, H. P. (1986). Relationship between silicosis and rheumatoid arthritis. Thorax, 41(8), 596-601.
  65. Smit MD, W. J.-v. (2012). Periodontitis in established rheumatoid arthritis patients: a cross-sectional clinical, microbiological and serological study. Arthritis Res Ther(14), 222.
  66. Smolen JS, L. R. (2014). EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis, 73(3), 492-509.
  67. Spector TD, H. M. (1990). The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytic epidemiological studies using meta-analysis. J Clin Epidemiol, 43(11), 1221-30.
  68. Spector TD, R. E. (1990). The pill, parity, and rheumatoid arthritis. Arthritis Rheum, 33(6), 782-9.
  69. Spindler A, B. V. (2002). Prevalence of rheumatoid arthritis in Tucuman, Argentina. J Rheumatol, 29(6), 1166–1170.
  70. St. Clair E.W., P. D. (2004). Rheumatoid Arthritis. USA: Lippincott Williams & Wilkins.
  71. Stastny P. (1978). Association of the B-cell alloantigen DRw4 with rheumatoid arthritis. N Engl J Med(298), 869–871.
  72. StataCorp. (n.d.). StataCorp. 2013. Stata Statistical Software: Release 13. College Station, TX: StataCorp LP.
  73. Steenland K, S. W. (2001). Kidney disease and arthritis in a cohort study of workers exposed to silica. Epidemiology, 12(4), 405-12.
  74. Steere A.C., Glickstein L. (2004). Elucidation of Lyme arthritis. Nature Reviews Immunology, 4, 143-152.
  75. Stitik T, A. E. (2006). Pharmacotherapy of osteoarthritis. Am J Phys Med Rehabil, 85(Suppl), S15–S28.
  76. Stolt P, P. L. (2005). Silica exposure is associated with increased risk of a restricted sub-group of RA: Results from the Swedish EIRA study. Ann Rheum Dis(64), 582–586.
  77. Stolt P1, B. C., & group, E. s. (2003). Quantification of the influence of cigarette smoking on rheumatoid arthritis: results from a population based case-control study, using incident cases. Ann Rheum Dis, 62(9), 835-41.
  78. Superio-Cabuslay E, W. M. (1996). Patient education interventions in osteoarthritis and rheumatoid arthritis: a meta-analytic comparison with non-steroidal anti inflammatory drug treatment. Artritis Care Res, 9(4), 292—301.
  79. Symmons D.P.M. (2002). Epidemiology of rheumatoid arthritis: Determinants of onset, persistence and outcome. Best Prac. Res. Clin. Rheumatol., 16(5), 707-722.
  80. Symmons DP, B. C. (1997). Blood transfusion, smoking, and obesity as risk factors for the development of rheumatoid arthritis: results from a primary care-based incident case-control study in Norfolk, England. Arthritis Rheum, 40(11), 1955-61.
  81. Szebenyi B, H. A. (2006). Associations between pain, function, and radiographic features in osteoarthritis of the knee. Arthritis Rheum, 54, 230–5.
  82. Szoeke C, D. L. (2006). The relationship between prospectively assessed body weight and physical activity and prevalence of radiological knee osteoarthritis in postmenopausal women. J Rheumatol, 33(9), 1835-40.
  83. Tapandinhas MJ, R. I. (1981). Oral glucosamine sulfate in the management of arthrosis: report on a multi–center open investigation in Portugal. Pharmatherapeutica(3), 157-168.
  84. Tascioglu F, A. O. (2004). Low power laser treatment in patients with knee osteoarthritis. Swiss Medical Weekly, 134(17-18), 254-8.
  85. Terkeltaub R. (2012). Gout and other crystal arthropathies. (R. Terkeltaub, Ed.) Philadelphia, USA: Saunders, Elsevier Inc.
  86. The American Academy of Orthopaedic Surgeons. (2013). Treatment of Osteoarthritis of the Knee (2nd Edition ed.). USA.
  87. The Royal Australian College of General Practitioners. (July 2009). Guideline for the non-surgical management of hip and knee osteoarthritis. 68.
  88. Toivanen AT, H. M. (2010). Obesity, physically demanding work and traumatic knee injury are major risk factors for knee osteoarthritis e a population-based study with a follow-up of 22 years. Rheumatology, 49(2), 308e14.
  89. Torisu M, M. T. (1978). A new side eff ect of BCG immunotherapy—BCG-induced arthritis in man. Cancer Immunol Immunother(5), 77-83.
  90. Towheed TE, M. L. (2005). Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev(2), CD002946.
  91. Towheed TE, M. L. (2006). Acetaminophen for osteoarthritis. Cochrane Database of Systematic Reviews(1), CD004257.
  92. Turesson C, J. L. (2004). Epidemiology of extra-articular manifestations in rheumatoid arthritis. Scand J Rheumatol, 33(2), 65-72.
  93. Turesson C1, S. D.-W. (2006). Association of HLA-C3 and smoking with vasculitis in patients with rheumatoid arthritis. Arthritis Rheum, 54(9), 2776-83.
  94. Turner S, Cherry N. (2000). Rheumatoid arthritis in workers exposed to silica in the pottery industry. Occup Environ Med, 57(7), 443-7.
  95. Uhlig T, H. K. (1999). Current tobacco smoking, formal education, and the risk of rheumatoid arthritis. J Rheumatol, 26(1), 47-54.
  96. Vagal M. (2004). Medial taping of patella with dynamic thermotherapy – a combined treatment approach for osteoarthritis of knee joint. The Indian Journal of Occupational Therapy, 36(2).
  97. van der Helm-van Mil AH, V. K. (2006). The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis. Arthritis Rheum(54), 1117-1121.
  98. van Raaij TM, R. M.-Z. (2010). Medial knee osteoarthritis treated by insoles or braces: a randomized trial. Clin Orthop Relat Res, 468(7), 1926-32.
  99. Verbuggen G, G. S. (2002). Systems to assess the progression of finger joint osteoarthritis and the effect of disease modifying osteoarthritis drugs. Clin Rheum(21), 231-243.
  100. Verpoort KN1, P.-v. d.-v.-v. (2007). Association of smoking with the constitution of the anti-cyclic citrullinated peptide response in the absence of HLA-DRB1 shared epitope alleles. Arthritis Rheum, 56(9), 2913-8.
  101. Vivar N., VanVollenhoven R.F. (2014). Advancesin thetreatmentofrheumatoidarthritis. F1000PrimeReports(6), 31.
  102. Voigt LF, K. T. (1994). Smoking, obesity, alcohol consumption, and the risk of rheumatoid arthritis. Epidemiology, 5(5), 525-32.
  103. Waldman S.D. (2011). Pain Management (2 ed.). (S. D. Waldman, Ed.) Philadelphia, USA: Elsevier Inc.
  104. Wandel S, J. P. (2010). Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis. BMJ, 341, c4675.
  105. Weisman M.H., W. M. (2010). Targeted treatment of the rheumatic diseases. (M. H. al.], Ed.) Philadelphia, USA: Saunders, Elsevier Inc.
  106. Wen H, Baker JF. (2011). Vitamin D, immunoregulation, and rheumatoid arthritis. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 17(2), 102–7.
  107. Weyand C.M., H. K. (1994). Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med(121), 484-91.
  108. White A, F. N. (2006). The effectiveness of acupuncture for osteoarthritis of the knee – a systematic review. Acupuncture in Medicine, 24(Suppl), s40-8.
  109. White DK, T.-L. C. (2014). Daily Walking and the Risk of Incident Functional Limitation in Knee Osteoarthritis: An Observational Study. Arthritis Care Res, 66(9), 1328-1336.
  110. White WB, W. C. (2007). Risk of cardiovascular events in patients receiving celecoxib: a metaanalysisof randomized clinical trials. Am J Cardiol, 99(1), 91-98.
  111. WHO (Geneva). (June 1997). Preventing and Managing the Global Epidemic of Obesity . Report of the World Health Organization Consultation of Obesity.
  112. Witt CM, J. S. (2006). Acupuncture in patients with osteoarthritis of the knee or hip: A randomized, controlled trial with an additional nonrandomized arm. Arthritis & Rheumatism, 3485-93.
  113. Wolfe F, K. S. (1988). Prevalence of familial occurrence in patients with rheumatoid arthritis. Br J Rheumatol, 27(Suppl 2), 150-2.
  114. Wolfe F, M. D. (1994). The mortality of rheumatoid arthritis. Arthritis Rheum, 37(4), 2529–33.
  115. Wolfe F, Young DY. (1983). Rheumatoid arthritis and antecedent tonsillectomy. J Rheumatol, 10(2), 309-12.
  116. Wright A, Sluka K. (2001). Nonpharmacological treatments for musculoskeletal pain. The Clinical Journal of Pain, 17, 33-46.
  117. Wright WF, R. D. (2012). Diagnosis and management of Lyme disease. Am Fam Physician, 85(11), 1086–93.
  118. Yelin E.K. (1996). The cost of rheumatoid arthritis; absolute, incremental and marginal estimates. J Rheumatol(23), 47-51.
  119. Zhang W, D. M. (2010). EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis, 69, 483-489.
  120. Zhang W, D. M. (2010). EULAR evidence-based recommendations for the diagnosis of knee osteoarthritis. Ann Rheum Dis, 69, 483-489.
  121. Zhang W, D. M. (published online first 07.10.2004). EULAR evidence based recommendations for the management of hip osteoarthritis – report of a task force of the eular standing committee for international clinical studies including therapeutics (escisit). Ann Rheum Dis.
  122. Zhang W, N. G. (2009). OARSI recommendations for the management of hip and knee osteoarthritis. Part III: changes in evidence following systematic cumulative update of research published through January 2009. OsteoarthritisandCartilage(18), 476-499.
  123. .., .. (2011). . , 49(1), 89-95.
  124. .. (2003). . (4), 31-34.
  125. .., .. (2009). : . , 2(1), 32-41.
  126. .. (2001). . - (4), 10-18.
  127. .. (2013). (). - , 51(1), 52-58.
  128. .., .. (2010). . , 9(6), 78-104.
  129. .., . . (2004). , , . , 3(4), 28-34.
  130. .., .. (2003). . , 2(1), 51-56.
  131. .. (2006). . - (2s), 113-122.
  132. .., . . (2012). . . . , 129(10), 5-11.
  133. .., . . (2013). . - , 51(3), 324-331.
  134. .., . . (2013). - . (3), 33-40.
  135. .., . . (2001). . - (4), 48-55.
  136. .., .. (2004). . - (3), 37-39.
  137. .., . . (2010). -. - " "(3), 59-63.
  138. .., .. (2011). . . . (7), 36-44.
  139. . . (2009). . : .
  140. .. (2011). : . (2), 6-8.
  141. .., . . (2010). - «»: . (2), 5-11.
  142. .. (2010). () : . (3), 10-17.
  143. .. (2013). . (1), 12-17.
  144. .. (2009). : . (2), 45-53.
  145. .., . . (1988). . : .
  146. .., .. (2013). . , XX(2), 169-173.
  147. .., .. (2007). : . , 15(14), 14-18.
  148. .., . . (2012). - ( 1). - , 51(2), 44-49.
  149. .., .. (2005). . - (5), 67-70.
  150. .., . . (2009). . - (1), 11-17.
  151. .., . . (2011). (Ixodidae) 2003-2009 . . .. , 2(2), 45-51.
  152. .., . . (2006). : . - (2), 31.
  153. .., .. (2005). . - (6), 63-69.
  154. .., . . (2013). - . , (2), 153-155.
  155. () . (..).
  156. O.A. (2007). : . - (2), 128.
  157. .. (2011). - . , -.
  158. .. (2012). : , . , 11(3), 28-33.
  159. .., . . (2013). . . II. , - . - , 51(6), 703-10.
  160. .., . . (2013). . . I. , . - , 51(5), 569-73.
  161. .., .. (2010). . - (2), 43-48.
  162. .. (2002). : . .. . «»(546), 42-46.
  163. .. (2014). . - , 52(2), 141-146.
  164. .., .. (2011). ((R)) . (3), 34-36.
  165. .., . . (2014). 1? . - , 52(1), 99-101.
  166. .., . . (2011). . (4), 35-38.
  167. .., .. (2007). . (1), 59-63.
  168. .., . . (2013). . - , 51(1), 44-47.
  169. .., .. (2005). ( ) . - (3), 42-46.
  170. ., . . (2014). , . - , 52(3), 290-294.
  171. .., . . (2011). : . (2), 35-36.
  172. .., . . (2009). . - (4), 84-89.
  173. .., . . (2010). : , . (1), 11-22.
  174. .., .. (2013). . (4), 47-53.
  175. .., .. (2010). - . - (4 ( 2)), 27-31.
  176. .., . . (2011). ACR/EULAR 2010 - . - (1), 10-15.
  177. .., .. (2008). . - (1), 5-16.
  178. .., . . (2013). : . (4), 26-32.
  179. .., .. (2012). . (4), 40-48.
  180. .., . . (2012). . , 9(3), 52-57.
  181. .., .. (2009). . - (3), 29-37.
  182. .., . . (2012). - . , 93(3), 519-521.
  183. .., . . (2012). . - , 52(3), 55-59.
  184. .., .. (2014). . - , 4(4), 386.
  185. .., .. (2008). . . . (. , .) : -.
  186. .., . . (2006). . : .
  187. .., .. (2004). -, . - (2), 53-58.
  188. .. (2009). : . (3), 39-44.
  189. .. (2014). - . (2), 66—70.
  190. .. (2014). - . , 04(1), 159-162.
  191. .. (2013). - . (4), 97-100.
  192. . (..). ( 2000-2006 .).
  193. .., . . (2005). - . , 34(1).
  194. ., . . (2011). - . - (1), 78-93.
  195. B.C., .. (2009). : ( BeST). (1), 56-60.
  196. .., . . (2010). ( ). (5), 9-14.
  197. .. (2014). XXI . - (2(52)), 133-137.
  198. .., . . (2010). : . (. . .., .) : -.
  199. .., .. (2014). . - , 52(3), 311-321.
  200. A.A. (2002). . . , & . . A.A. (.), A.A. , .. .: «», .: «-» (. 170-180). -, : , -.
  201. .. (2013). - . , 94(6), 920-923.
  202. .. (2010). . . (1), 66-70.
  203. .., . . (2012). . - , 52(3), 68-74.
  204. .., . . (2011). : . I - , , . - (6), 78-89.
  205. .., . . (2013). : 6- . - , 51(4), 398–406.
  206. .., . . (2014). : . , 2(4(80)), 96-99.
  207. .., .. (2011). : . - (3), 38-45.
  208. .., . . (2005). . - (2), 70-75.
  209. .. (2014). VI - EULAR, (, , 1–6 2013 .). - , 52(4), 230-237.
  210. .., .. (2009). . (1), 21-24.
  211. .., . . (2013). - . (3), 53-7.
  212. .., . . (2013). . - , 51(1), 48-51.
  213. .., . . (2011). . (4), 53-56.
  214. .., . . (2002). . - (4), 55-58.
  215. .., . . (2013). . , 81(6), 70-75.
  216. .., . . (2012). . - , 50(1), 75-82.
  217. .. (2013). . (1), 66-72.
  218. .., .. (2009). . , 50(2).
  219. .., .. (2005). . - (5), 71-75.
  220. .. (1994). . . - (. 121-2). : .
  221. .., .. (2009). . -. (6), 73-84.
  222. . (2006).
  223. .. (2010). . , .
  224. aylor W., G. D. (2006). Classification criteria for psoriatic arthritis: development of new criteria from a large international study. ArthritisRheum(54), 2665-73.
  225. .. (2011). , . . . , 19(3), 106-112.
  226. .. (1993). . , , (. 188). .
  227. .., . . (2012). : . , 58(3), 17-22.
  228. .., . . (2010). : . .. ( ) , (. 38). .
  229. .., . . (2012). ( ) , ( 1). 0 , 84(2), 67-70.
  230. .., . . (2010). : . () (RAISER). - (1), 50-60.
  231. .., . . (2005). 5- (19993-2003 ..). (5), 18-22.
  232. .., . . (2009). . - (4), 49-54.
  233. .., . . (2013). . , 94(4), 545-548.
  234. .., . . (2013). (). - , 9(2), 308-313.
  235. .. (2010). . (3), 165-168.
  236. .. (2014). EULAR (2013): . (2), 17-23.
  237. ?.., .. (2014). . (7), 31-33.
  238. .., . . (2013). HLA . . . .2(7), 31-33.
  239. .. (2010). . , 7(4), 117-151.
  240. — . , SF-36. (2009).
  241. .. (2013). ( ). - , 51(6), 686-95.
  242. .., . . (2013). . - , 51(6), 604-8.
  243. .., .. (2010). - : , . - (1), 77-85.
  244. .., .. (2004). . , 12(2004), 1121-1123.
  245. .., .. (2013). . , 73(1-4), 24-28.
  246. .., .. (2011). . (04 (11)), http://pmarchive.ru/osobennosti-rasprostranennosti-i-klinicheskogo-techeniya-revmatoidnogo-artrita-v-respublike-tatarstan-u-gorodskix-i-selskix-pacientov/.
  247. .., . . (2006). - ( ). - (2), 211.
  248. .. (2013). - - . , 40(3-2), 54-60.

 

‹‹        ››

 

 


? !


:

:
:


,

    ...